NEW YORK (GenomeWeb News) – Abbott today reported 3 percent first quarter growth for its diagnostics business including a 5 percent increase in year-over-year molecular diagnostics sales.

The firm reported overall diagnostics dales of $1.12 billion for the three months ended March 31, up from $1.09 billion for Q1 2013. On an operational basis, its diagnostics sales were up 5 percent. It said that the diagnostics business was hit by a 2.5 percent negative effect from foreign exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.